Rocket Lab USA’s Return On Capital Employed Overview

According to Benzinga Pro data, during Q3, Rocket Lab USA (NASDAQ:RKLB) posted sales of $63.06 million. Earnings were…

According to Benzinga Pro data, during Q3, Rocket Lab USA (NASDAQ:RKLB) posted sales of $63.06 million. Earnings were up 7.5%, but Rocket Lab USA still reported an overall loss of $34.61 million. Rocket Lab USA collected $55.47 million in revenue during Q2, but reported earnings showed a $37.42 million loss.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Rocket Lab USA posted an ROCE of -0.05%.

Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Rocket Lab USA is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Rocket Lab USA, a negative ROCE ratio of -0.05% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Rocket Lab USA reported Q3 earnings per share at $-0.07/share, which did not meet analyst predictions of $-0.07/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Aurora Reports 20% YoY Uptick In Global Medical Marijuana, Expects Benefits From International Cannabis Regulatory Reforms

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced on Thursday its financial and operational results for the fourth quarter and fiscal year 2024.The company reported a 5% year-over-year increase in revenue to CA$67.4 million ($49.1 million) in the fourth quarter. Global medical cannabis net revenue grew by 20% over the same period to CA$45.6 million. The increase in net revenue1 of $7.7 million was primarily due to higher sales to Australia and Europe in the current period following the success of newly launched innovative cultivars in these markets. 

ACB